EyePoint Pharmaceuticals, Inc. (EYPT)
After hours:
| Previous close | 11.20 |
| Open | 11.20 |
| Bid | 11.79 x 300 |
| Ask | 11.92 x 600 |
| Day's range | 10.65 - 11.89 |
| 52-week range | 5.67 - 30.99 |
| Volume | |
| Avg. volume | 1,130,104 |
| Market cap | 618.238M |
| Beta (5Y monthly) | 1.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.82 |
| Earnings date | 07 May 2024 - 12 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 42.00 |
GlobeNewswireEyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no drug-related serious adverse events – – Conference call to discuss the results to be held at 8:00 a.m. ET – WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of pat
- GlobeNewswire
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggr
- GlobeNewswire
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD – - Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 - WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a
